AUPH on Nasdaq
Aurinia Pharmaceuticals Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Intercept Pharmaceuticals, Xeris Biopharma Holdings, Inc. or Harrow Health, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 96% of the revenue Aurinia Pharmaceuticals Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $158.5M | $216.2M | $271.3M |
| License, Collaboration and Royalty Revenue | $17.0M | $18.9M | $11.7M |
Regions
United States brought in 93% of the revenue Aurinia Pharmaceuticals Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $158.0M | $210.1M | $263.8M |
| Japan | $17.6M | $25.0M | $19.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue6¢$32.7M
- Research and development6¢$32.5M
- Income tax33¢$173.0M
- Profit55¢$287.2M
Out of $283.1M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Share buybacks72¢$98.2M
- Kept or used elsewhere28¢$37.5M
Out of $135.7M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $283.1M | $235.1M | $175.5M |
| Cost of revenue | $32.7M | $28.2M | $14.1M |
| Selling, general and administrative | $101.8M | $172.0M | $195.0M |
| Research and development | $32.5M | $20.8M | $49.6M |
| Restructuring | $1.6M | $23.1M | $0 |
| Other expense (income), net | $9.5M | -$4.3M | $8.4M |
| Total operating expenses | $178.1M | $239.8M | $267.2M |
| Income (loss) from operations | $104.9M | -$4.7M | -$91.7M |
| Interest income | $13.6M | $17.0M | $17.0M |
| Interest expense | -$4.3M | -$4.8M | -$2.8M |
| Net income (loss) before income taxes | $114.2M | $7.4M | -$77.5M |
| Income tax (benefit) expense | -$173.0M | $1.7M | $551.0K |
| Net income (loss) | $287.2M | $5.8M | -$78.0M |
| Unrealized gain on available-for-sale securities | $48.0K | $83.0K | $331.0K |
| Comprehensive income (loss) | $287.2M | $5.8M | -$77.7M |
| Basic (in usd per share) | $2.14 | $0.04 | -$0.54 |
| Diluted (in usd per share) | $2.07 | $0.04 | -$0.54 |
| Basic (in shares) | 134.4M shares | 143.1M shares | 143.2M shares |
| Diluted (in shares) | 138.7M shares | 146.2M shares | 143.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $80.2M | $83.4M | $48.9M |
| Short-term investments | $317.8M | $275.0M | |
| Accounts receivable, net | $41.5M | $36.5M | |
| Inventory | $45.7M | $39.2M | |
| Prepaid expenses and deposits | $5.7M | $11.2M | |
| Other current assets | $1.1M | $1.1M | |
| Total current assets | $492.0M | $446.6M | |
| Deferred tax assets, net | $176.2M | $0 | |
| Finance right-of-use lease assets | $73.9M | $92.1M | |
| Intangible assets, net | $3.8M | $4.4M | |
| Operating right-of-use lease assets | $3.6M | $4.1M | |
| Property and equipment, net | $2.1M | $2.7M | |
| Other noncurrent assets | $93.0K | $823.0K | |
| Total assets | $751.6M | $550.6M | |
| Accounts payable | $3.3M | $5.2M | |
| Accrued expenses | $66.6M | $65.0M | |
| Finance lease liabilities, current portion | $16.5M | $14.0M | |
| Deferred revenue | $3.7M | $11.0M | |
| Operating lease liabilities, current portion | $1.1M | $1.0M | |
| Other current liabilities | $2.5M | $1.5M | |
| Total current liabilities | $93.7M | $97.8M | |
| Finance lease liabilities, less current portion | $52.3M | $58.6M | |
| Deferred revenue, less current portion | $12.6M | $1.7M | |
| Deferred compensation and other noncurrent liabilities | $6.7M | $9.4M | |
| Operating lease liabilities, less current portion | $4.9M | $5.7M | |
| Total liabilities | $170.3M | $173.2M | |
| Common shares - no par value, Unlimited shares authorized, 132,323 and 140,883 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1.1B | $1.2B | |
| Additional paid-in capital | $111.3M | $127.0M | |
| Accumulated other comprehensive loss | -$599.0K | -$647.0K | |
| Accumulated deficit | -$649.4M | -$936.6M | |
| Total shareholders' equity | $581.3M | $377.5M | $378.0M |
| Total liabilities and shareholders' equity | $751.6M | $550.6M | |
| Common stock, par value (in usd per share) | $0.00 | $0.00 | |
| Common stock, issued (in shares) | 132.3M shares | 140.9M shares | |
| Common stock, outstanding (in shares) | 132.3M shares | 140.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $287.2M | $5.8M | -$78.0M |
| Deferred income tax benefit | -$176.2M | $0 | $0 |
| Amortization and depreciation | $19.4M | $19.4M | $11.6M |
| Share-based compensation | $14.7M | $31.6M | $45.3M |
| Foreign exchange loss (gain) on revaluation of Monoplant finance lease liability | $9.7M | -$5.9M | $5.9M |
| Net amortization of premiums and discounts on investments | -$10.2M | -$12.7M | -$12.1M |
| Non-cash write-down of inventory | $0 | $0 | $916.0K |
| Other, net | -$200.0K | $788.0K | -$1.5M |
| Accounts receivable, net | -$4.9M | -$12.5M | -$10.6M |
| Inventory | -$6.5M | $477.0K | -$15.9M |
| Prepaid expenses and other current assets | $5.5M | -$1.8M | $4.4M |
| Other noncurrent operating assets | $730.0K | $31.0K | -$16.0K |
| Accounts payable | -$1.9M | $860.0K | $1.2M |
| Accrued expenses and other liabilities | -$4.7M | $13.3M | $12.2M |
| Deferred revenue | $3.7M | $5.8M | $3.8M |
| Operating lease liabilities | -$802.0K | -$750.0K | -$673.0K |
| Cash flows from operating activities | $135.7M | $44.4M | -$33.5M |
| Proceeds from the sale and maturities of investments | $494.1M | $585.4M | $529.4M |
| Purchases of investments | -$526.6M | -$545.8M | -$523.5M |
| Upfront lease payments | $0 | -$43.0K | -$11.9M |
| Purchases of property, equipment and intangible assets | -$252.0K | -$281.0K | -$718.0K |
| Cash flows from investing activities | -$32.8M | $39.3M | -$6.7M |
| Repurchase of common shares | -$98.2M | -$40.2M | $0 |
| Principal portion of finance lease payments | -$13.1M | -$12.0M | -$10.0M |
| Proceeds from issuance of common shares from exercise of stock options and vesting of RSUs and performance awards | $14.2M | $8.2M | $5.3M |
| Proceeds from issuance of common shares under ESPP | $756.0K | $1.1M | $1.9M |
| Taxes paid related to net settlement of exercises of stock options and vesting of RSUs and performance awards | -$9.8M | -$6.1M | -$2.3M |
| Cash flows from financing activities | -$106.1M | -$49.1M | -$5.1M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$3.2M | $34.6M | -$45.3M |
| Finance lease liability arising from obtaining right-of-use assets | $0 | $0 | $94.1M |
| Cash paid for income taxes | -$2.8M | -$2.2M | -$496.0K |
| Taxes withheld related to vesting of performance awards | $3.8M | $0 | $0 |
Recent filings
- Sep 11, 20264
- Aug 26, 2026SCHEDULE 13D/A
- Aug 25, 20264
- Aug 21, 2026144
- Aug 19, 20268-K
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jun 8, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 8, 20264
- Jun 5, 2026144
- Jun 4, 2026144
- Jun 4, 20268-K
- Jun 4, 2026SCHEDULE 13D/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11